These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 21420993

  • 1. Aromatase inhibitors and xenograft studies.
    Chumsri S, Sabnis GJ, Howes T, Brodie AM.
    Steroids; 2011 Jul; 76(8):730-5. PubMed ID: 21420993
    [Abstract] [Full Text] [Related]

  • 2. Functional activation of the estrogen receptor-α and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole.
    Sabnis GJ, Goloubeva O, Chumsri S, Nguyen N, Sukumar S, Brodie AM.
    Cancer Res; 2011 Mar 01; 71(5):1893-903. PubMed ID: 21245100
    [Abstract] [Full Text] [Related]

  • 3. Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen.
    Sabnis G, Schayowitz A, Goloubeva O, Macedo L, Brodie A.
    Cancer Res; 2009 Feb 15; 69(4):1416-28. PubMed ID: 19190349
    [Abstract] [Full Text] [Related]

  • 4. HDAC inhibitor entinostat restores responsiveness of letrozole-resistant MCF-7Ca xenografts to aromatase inhibitors through modulation of Her-2.
    Sabnis GJ, Goloubeva OG, Kazi AA, Shah P, Brodie AH.
    Mol Cancer Ther; 2013 Dec 15; 12(12):2804-16. PubMed ID: 24092810
    [Abstract] [Full Text] [Related]

  • 5. Histone deacetylase inhibitor entinostat in combination with a retinoid downregulates HER2 and reduces the tumor initiating cell population in aromatase inhibitor-resistant breast cancer.
    Schech AJ, Shah P, Yu S, Sabnis GJ, Goloubeva O, Rosenblatt P, Kazi A, Chumsri S, Brodie A.
    Breast Cancer Res Treat; 2015 Aug 15; 152(3):499-508. PubMed ID: 26133921
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Understanding resistance to endocrine agents: molecular mechanisms and potential for intervention.
    Sabnis G, Brodie A.
    Clin Breast Cancer; 2010 Feb 15; 10(1):E6-E15. PubMed ID: 20133251
    [Abstract] [Full Text] [Related]

  • 12. Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole.
    Jelovac D, Sabnis G, Long BJ, Macedo L, Goloubeva OG, Brodie AM.
    Cancer Res; 2005 Jun 15; 65(12):5380-9. PubMed ID: 15958587
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The importance of HER2 signaling in the tumor-initiating cell population in aromatase inhibitor-resistant breast cancer.
    Gilani RA, Kazi AA, Shah P, Schech AJ, Chumsri S, Sabnis G, Jaiswal AK, Brodie AH.
    Breast Cancer Res Treat; 2012 Oct 15; 135(3):681-92. PubMed ID: 22878889
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.